Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2019—Prelude Corp. presented interim results from its Predict study during a poster presentation at the American Society of Breast Surgeons annual meeting, April 30–May 5, in Dallas (Abstract 581643).
July 2019—HemoSonics announced that its Quantra Hemostasis Analyzer platform and QPlus cartridge have been granted de novo marketing authorization by the FDA and are available for sale in the United States.
July 2019—Anpac Bio-Medical Science Company announced that its subsidiary Anpac Technology USA achieved CLIA certification for its San Jose, Calif.-based laboratory.
June 2019—Ortho Clinical Diagnostics’ Vitros XT MicroSlides have been cleared by the FDA. The product features multitest technology that allows laboratories to run two tests simultaneously on one MicroSlide.
June 2019—The Food and Drug Administration approved pembrolizumab (Keytruda, Merck) plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma. Approval was based on Keynote‑426, a randomized, multicenter, open-label trial conducted in 861 patients who had not received systemic therapy for advanced renal cell carcinoma. Patients were enrolled regardless of PD-L1 tumor expression status.
June 2019—Positive data demonstrating the clinical value of ConfirmMDx and SelectMDx (MDxHealth, Irvine, Calif.) for prostate cancer were presented in two moderated posters at the American Urological Association annual meeting, May 1–6 in Chicago.
June 2019—BD announced the worldwide availability of its FDA-cleared and CE-marked BD Bactec platelet quality control media to identify contaminated platelet units. The product can be used for quality control testing of leukocyte-reduced apheresis platelet units: leukocyte-reduced single and a pool of up to six units of leukocyte-reduced whole blood platelet concentrates.
June 2019—Group K Diagnostics has signed an agreement with the Centers for Disease Control and Prevention to design and evaluate a prototype reverse transcriptase loop-mediated isothermal amplification assay for the detection of the Zika virus RNA that can be performed by clinical personnel or health care practitioners where real-time RT-PCR instrumentation is not available.
June 2019—GenMark Diagnostics received FDA 510(k) clearance for its ePlex Blood Culture Identification Gram-Negative Panel.
June 2019—PerkinElmer, in collaboration with Helix, launched a genetic screening test called GenePrism: Actionable Insights, which analyzes a subset of 59 medically actionable genes, including BRCA1 and BRCA2, identified by the American College of Medical Genetics and Genomics.
